Navigation Links
BSP Raises $2.6 Million Dollars From Private Investors

TEL AVIV, Israel, June 17 /PRNewswire-FirstCall/ -- BSP Ltd., ( an Israeli company which develops and markets systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease, announced that they successfully raised $2.6 million in a private funding round, that included existing shareholders in the company as well as new investors.

BSP developed the HyperQ(TM), a cutting-edge technology that offers highly reliable, low-cost and risk free cardiac monitoring for broad populations and allows, for the first time, effective and accurate testing for Ischemic Heart Disease - the No. 1 killer in the world.

Thousands of patients in Israel, Europe and the US have already been examined by HyperQ(TM) Stress Systems in controlled clinical studies, pilot programs and routine testing. The results have demonstrated the system's high efficiency and unmatched accuracy in the diagnosis of IHD. The HyperQ(TM) system received FDA clearance (510K), as well as the European CE marking.

The company has entered the clinical and commercial phase, during which the HyperQ(TM) Stress System will be integrated in inpatient and outpatient hospital settings, private doctor offices and major research centers.

Further applications on the company's scope; include bedside monitors for ischemic events; devices for cardiac home-care and telemedicine; and the implementation of the HyperQ(TM) technology in implantable cardiac devices.

"The completion of this round reflects our investors' ongoing confidence in our ability to meet our commercial and clinical milestones. This round will enable us to step-up the marketing and business development efforts in the US, and accelerate development of BSP's next application - the HyperQ bedside monitor," said Dr. Amir Beker, CEO of BSP.

Dr. Beker added, "The HyperQ(TM) technology is a revolutionary non-invasive solution to today's most fatal pathology. It improves the standard of care for cardiac patients, decreases the risk of further, often invasive, tests, and addresses the dire needs of private and national healthcare systems to balance the immense costs of cardiac diagnosis and monitoring."

About BSP

BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP was founded in 2000 by Dr. Amir Beker and Mr. Ariel Landau and has completed a successful IPO in mid-2006 and its shares are traded on the Tel Aviv Stock Exchange. Visit:

Contact: Dr. Amir Beker, CEO or Dr. Neri Malka, Head of Clinical Marketing: +972-3-6474840

SOURCE BSP - Biological Signal Processing Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
2. Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
3. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
4. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
5. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
6. Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%.
7. Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance
8. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
9. Stemline Therapeutics Raises $12.5 Million
10. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
11. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
Post Your Comments:
(Date:10/12/2015)...  Rebiotix Inc. today announced that U.S. Food ... Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough ... difficile (C diff) infection, a challenging to ... in the U.S. annually. 1 Rebiotix is ... to revolutionize the treatment of debilitating GI diseases ...
(Date:10/12/2015)... 12, 2015  Patara Pharma, a clinical-stage biotechnology ... diseases and conditions, today announced the closing of ... Concurrent with the close of its sale of ... and Security Agreement with Silicon Valley Bank whereby ... Patara will use the funds from the financing ...
(Date:10/12/2015)... ... October 12, 2015 , ... Dr. Carl Peck, MD, Chairman ... firm as a Premier Expert consultant. NDA Partners Premier Experts are top ... to the company's clients. Premier Experts collaborate to design and implement critical ...
(Date:10/10/2015)... 10 octobre 2015 Le 8 octobre, l,honorable Doris ... Registre du Congrès sa déclaration de soutien à ... autour du plasma (IPAW), qui se tiendra du ... Plasma Protein Therapeutics Association (PPTA) et ... , Sensibiliser l,opinion publique mondiale autour du ...
Breaking Biology Technology:
(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/29/2015)... , Sept. 29, 2015  iDAvatars is excited to ... introduce its product to market. The official announcement was recently ... Economy event in San Francisco , ... platform powered by IBM Watson. "It is both ... first 100 companies to bring to market the cognitive power ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
Breaking Biology News(10 mins):